INCYIncyte CorporationFinished
Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies
Melanoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 61 (final count)
- Started
- Jul 27, 2020
- Main results expected
- Aug 25, 2025
- Fully finished
- Aug 25, 2025
- Results posted
- Aug 17, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase 1: Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
Measured over: up to 1148 days
Phase 1: Number of Participants With Any ≥Grade 3 TEAE
Measured over: up to 1148 days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04370704 · record last updated 2026-08-17 · checked 2026-11-09 15:47 UTC